British national newspaper The Times reported on Thursday that senior sources in the British government expect that a verdict on whether US pharmaceutical company Pfizer Inc's (NYSE:PFE) COVID-19 vaccine works, will be available before the results are in on British pharmaceutical company AstraZeneca Plc's (STO:AZN)(LON:AZN) competing vaccine.
The Times report said that Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas.
Reportedly, Pfizer's Chief Executive, Albert Bourla, had previously said the company could release data on whether or not the vaccine works as early as October 2020.
Pfizer had said this week if trials are successful the company expects to file for emergency authorisation of the vaccine candidate from US regulators shortly after it has enough safety data in late November 2020.
According to Reuters news agency, Britain has supply deals for six vaccine candidates, including frontrunners from Pfizer and AstraZeneca.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100